Developing a New EEG Method for the Early Diagnosis of Dementia
Launched by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST · Apr 21, 2015
Trial Information
Current as of October 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to diagnose dementia, particularly Alzheimer's disease, using a method called EEG (electroencephalogram). EEG measures the electrical activity of the brain and is a non-invasive procedure, meaning it doesn't require any surgery or special instruments inside the body. The researchers have developed special software to analyze the EEG data, and they are looking for people with Alzheimer's disease as well as healthy volunteers aged 65 to 74 to participate in the study.
To be eligible for this trial, participants need to have a clinical diagnosis of possible or probable Alzheimer's disease. However, those with significant brain changes seen on imaging, a history of certain neurological disorders (like stroke or severe epilepsy), moderate to severe dementia, or severe mental health issues cannot participate. If you join the study, you can expect to undergo an EEG test, which is painless and quick, while helping researchers learn more about early diagnosis of dementia. Your contribution could be vital in improving how we understand and diagnose this condition in the future!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Clinical diagnosis of possible or probable AD (according to revised diagnostic criteria (McKhann et al., 2011, Dubois et al., 2007)
- Exclusion Criteria:
- • Significant vascular change on neuro-imaging (Fazekas grading of white matter change \>2) (Fazekas et al., 2002).
- • Clinical history of stroke, Parkinsonism, epilepsy or other neurological disorder. (e.g. severe auditory, visual, language or motor impairment)
- • Moderate to severe dementia (defined by research team but we wouldn't expect those with a mini mental state exam \[MMSE\] ≤ 18 to be able to participate)
- • Severe current mental health disorder (depression, psychosis).
- • Patients on sedating or antiepileptic medication
About Sheffield Teaching Hospitals Nhs Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust is a leading healthcare institution in the UK, dedicated to delivering high-quality patient care, advancing medical research, and fostering education and training in the health sector. As a prominent sponsor of clinical trials, the Trust collaborates with various stakeholders to facilitate innovative research initiatives that aim to improve treatment outcomes and enhance patient safety. With a commitment to excellence, the organization leverages its extensive clinical expertise and resources to support the development of new therapies and interventions, ultimately contributing to the advancement of healthcare practices both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sheffield, S Yorks, United Kingdom
Patients applied
Trial Officials
Daniel Blackburn, MBChB, PhD
Principal Investigator
Sheffield Teaching Hospitals NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials